ImmunoMolecular Therapeutics (“IM Therapeutics”) is a clinical stage company developing personalized therapies for autoimmune disease.
IMT is the first company to target the root cause of autoimmunity with therapeutic design directed at HLA variants known to confer high disease risk.
IM Therapeutics was founded in 2016 by Aaron Michels and Peter Gottlieb. The company is headquartered in Woburn, Massachusetts, with an additional office in Aurora, Colorado.
IM Therapeutics is building an HLA-directed platform for new therapies. The company's novel therapies are designed to specifically block the action of HLA proteins known to be involved in the trigger of autoimmune response.
IM Therapeutics' platform builds drug molecules for specific blockade of an HLA protein in a given autoimmune disease as a novel paradigm in drug development. Its drug development of oral therapies employs a unique approach to balance the affinity to HLA binding site(s) to achieve blockade versus protecting inherent immunity against pathogens conferred by the HLA proteins.
IM Therapeutics' platform screens millions of compounds for optimal docking within HLA proteins together with rational drug design and bioassays to develop targeted therapeutic candidates. Its lead drug, IMT-002, is directed at HLA DQ8 activity for treatment of type 1 diabetes.
IM Therapeutics is backed by JDRF T1D Fund, Morningside Ventures, and Colorado University Healthcare Innovation Fund. The company has raised $10M from a latest financing on Oct 9, 2019.